Coherus Oncology, Inc.

Contributing Author

Recent Articles by Coherus Oncology, Inc.

Sep-23	Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets CHRS GlobeNewswire
Aug-31	Coherus to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Aug-17	Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights CHRS CHRS +16.52% GlobeNewswire
Aug-05	Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update CHRS CHRS -12.76% GlobeNewswire
Jul-22	Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 CHRS GlobeNewswire
Jun-23	Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) CHRS GlobeNewswire
May-11	Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update CHRS +11.43% CHRS -12.31% GlobeNewswire
May-04	Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 CHRS GlobeNewswire
Mar-09	Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update CHRS +6.04% GlobeNewswire
Mar-02	Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 CHRS GlobeNewswire
Feb-23	Coherus Oncology to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Feb-17	Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock CHRS GlobeNewswire
Feb-12	Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock CHRS -19.90% GlobeNewswire
Feb-12	Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock CHRS CHRS -19.90% GlobeNewswire
Jan-06	Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference CHRS -5.56% GlobeNewswire
Jan-05	Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) CHRS +5.11% GlobeNewswire
Dec-08	Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma CHRS +6.67% GlobeNewswire
Nov-07	Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody CHRS -10.07% GlobeNewswire
Nov-06	Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update CHRS GlobeNewswire
Nov-06	Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer CHRS CHRS -10.07% GlobeNewswire
Oct-30	Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 CHRS GlobeNewswire
Oct-23	Coherus Oncology to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Oct-03	Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) CHRS GlobeNewswire
Sep-03	Coherus Oncology to Participate in Upcoming Investor Conferences CHRS +5.88% GlobeNewswire
Aug-07	Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update CHRS CHRS -7.13% GlobeNewswire
Jul-31	Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 CHRS CHRS -6.64% GlobeNewswire
May-30	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics CHRS GlobeNewswire

Coherus Oncology, Inc.

Recent Articles by Coherus Oncology, Inc.

Upgrade your Finviz experience